TEANECK, N.J. — Phibro Animal Health Corp. has announced plans to establish a biotech facility producing a range of animal health vaccines on the IDA Ireland Finisklin Business Park in Sligo, Ireland, creating up to 150 jobs during the next 5 years.
The project is supported by the Irish Government through IDA Ireland.
Phibro had $764 million in annual sales in more than 65 countries during its most recent fiscal year and employs over 1,400 people globally. The Sligo plant will be the company’s first biologicals manufacturing location in Europe and will allow Phibro to expand its presence in Europe.
The new manufacturing facility will initially focus on producing Phibro’s line of vaccines for the treatment of a range of poultry diseases for sales globally. In the future, Phibro expects to expand production to include vaccines for livestock and aquaculture.
Making the announcement in Sligo on July 5, Irish Minister for Agriculture, Food and the Marine Michael Creed said, “This significant investment by Phibro is a great vote of confidence in Sligo, and will offer even more opportunities for local residents and communities to grow and thrive. It further strengthens Ireland’s Life Sciences capability in the North West and builds on a series of new IDA projects announced for Sligo and elsewhere in the region over recent times. The Government is tirelessly working to achieve job creation in locations which are away from the main cities, and this new biotech facility in Sligo is testament that the policy is working.”
Welcoming the announcement, Irish Minister for Business, Enterprise & Innovation Heather Humphreys said, “I was delighted to see Phibro announce that their first biologicals manufacturing location in Europe will be in Sligo, creating up to 150 highly skilled jobs. This has been a fantastic few weeks for Sligo with announcements from Abtran, E3 Retail, and Live Tiles, showing how the county is benefiting from both indigenous and FDI investment. This is another example of the success of our commitment under the Regional Action Plans for Jobs to ensure we have the right conditions in place to encourage job creation in regional locations.”
Jack Bendheim, Phibro’s chairman, president and CEO, said, “The creation of Phibro Ireland marks an important milestone in our development as a leading global player in the animal health biological market. The winning combination of Phibro’s expertise in the development and manufacture of biological products, the driven and experienced workforce available in the Sligo area, and the strong support of the IDA makes us very excited about the potential of the Sligo facility.”
“This announcement of a new company into Ireland, which is a global leader in diversified animal health and nutrition, is great news for Sligo and the North West Region,” said IDA Ireland’s Executive Director Mary Buckley. “IDA is committed to winning investments for regional locations across Ireland and the North West Border Region is a key area of focus for us. The 150 jobs being created by Phibro will significantly benefit the regional economy. I wish you and your team every success here and will follow your progress with interest.”
The new employment opportunities will include management, quality analysis, quality control, regulatory, engineering, operators and maintenance staff.
More information about Phibro Animal Health can be obtained at www.pahc.com.